Strikingly, KD of RBFOX2 markedly impaired human AML progression in immunocompromised recipient mice and significantly prolonged mice survival (Fig. 5d,e and Extended Data Fig. 7i). Here, RBFOX2 is linked to acute myeloid leukemia.